Join the club for FREE to access the whole archive and other member benefits.

Jesse Karmazin

CEO of the blood transfusion company Ambrosia.

Jesse Karmazian is the CEO of the blood transfusion company Ambrosia which he founded in 2014. He is based in the United States.

Karmazin graduated from Princeton University in 2007. He would earn his MD in 2014 from Stanford University.

Visit website: https://everipedia.org/wiki/lang_en/jesse-karmazin

 jessekarmazin

 jessekarmazinmd

See also: Company Ambrosia - Offers young blood plasma transfers after running a trial in 2016-18

Details last updated 12-Nov-2019

Jesse Karmazin Blog Posts

Ambrosia Plasma relaunches - announces improvement in key ageing biomarkers
03-Feb-2020

Ambrosia Plasma relaunches - announces improvement in key ageing biomarkers

The Club interviews Jesse Karmazin, CEO, to find out more about the trial, the FDA warning, and the relaunch

Jesse Karmazin News

Ambrosia young blood plasma treatments relaunched

Ambrosia young blood plasma treatments relaunched

OneZero - 08-Nov-2019

No further clinical trials planned, but some interesting results from initial trial

Young blood as a key to living longer

Young blood as a key to living longer

Wired - 09-May-2018

GDF11 is a protein in the blood, which can stimulate cell growth and repair

Young blood reduces ageing biomarkers in humans

Young blood reduces ageing biomarkers in humans

New Scientist - 31-May-2017

Update on Ambrosia trial that gives blood plasma from under 25s to older people. Recipients have...

Young blood antiaging trial raises questions

Young blood antiaging trial raises questions

Science - 01-Aug-2016

Ambrosia (https://www.ambrosiaplasma.com/) young plasma trial is open to anyone 35 and older. Pa...